European News

Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo’s HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201)

Bempedoic Acid CLEAR Serenity Study Results Published in the JAHA Demonstrated Significant LDL-Cholesterol Lowering and Reduced hsCRP in Statin Intolerant Patients

Daiichi Sankyo Confirms Plans to Accelerate BLA Submission to U.S. FDA for [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Positive Metastatic Breast Cancer Post T-DM1

Data from the Non-interventional EMIT-AF/VTE Study Shows Low Thromboembolic and Bleeding Event Rates in Unselected Elderly AF/VTE Patients on Oral, Once-Daily LIXIANA®▼ Undergoing Diagnostic or Therapeutic Procedures

CLEAR Wisdom Demonstrated First-in-Class, Oral, Once-daily, ACL inhibitor Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP

Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral, Once-daily LIXIANA®▼ (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter Ablation

Bempedoic Acid Study 1 results published in The New England Journal of Medicine demonstrated significant LDL-cholesterol lowering and reduced marker of underlying cardiovascular inflammation, with a similar tolerability to placebo

Daiichi Sankyo Announces New Data on Once-Daily LIXIANA®▼ (edoxaban) to be Presented in Late-Breaking Sessions at EHRA 2019, the Annual Congress of the European Heart Rhythm Association

Daiichi Sankyo Europe and Esperion Announce Validation of the Marketing Authorisation Application (MAA) for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet

Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase